Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Recent publications review
- Fibrosis and major organ systems
- Molecular pathways in fibrosis
- Orphan lung diseases
- Interstitial lung disease
- ATS/ERS classification of interstitial pneumonia
- Idiopathic interstitial pneumonia
- IPF prognosis
- IPF epidemiology
- IPF epidemiology - age groups
- IPF: median survival after diagnosis
- IPF: cause of death
- IPF: natural history
- Current paradigm of IPF pathogenesis
- Genome wide association study in IIP
- Mr. IPF
- Guidelines for diagnosis and management
- Diagnosis of IPF
- HRCT criteria for UIP pattern
- IPF diagnosis: HRCT & SLB patterns combination
- Lung biopsy to diagnose IPF
- Typical UIP pattern: trichrome stained section
- Histopathological criteria for UIP pattern
- Diagnostic algorithm for IPF
Topics Covered
- Fibrosis: a common pathway to organ failure
- Interstitial lung disease: idiopathic interstitial pneumonia
- Idiopathic Pulmonary Fibrosis: definition
- IPF epidemiology
- Causes of the disease
- Pathogenesis of IPF
- Diagnostic approach
Talk Citation
Richeldi, L. (2015, October 6). Diagnosis and treatment of idiopathic pulmonary fibrosis 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 27, 2024, from https://doi.org/10.69645/QTWE7502.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Luca Richeldi has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Diagnosis and treatment of idiopathic pulmonary fibrosis 1
Published on October 6, 2015
27 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Luca Richeldi.
I'm a professor
of respiratory medicine
at the University Hospital
of Southampton
in the United Kingdom.
And today, I will speak about
the diagnosis and treatment
of idiopathic
pulmonary fibrosis.
0:16
So before going into
the specifics and the details
of pulmonary fibrosis,
let me review with you
this recent article published
in the New England
Journal of Medicine.
And discussing
the topic of fibrosis,
which as you see
is defined as a common pathway
to organ injury and failure.
And there are at least
three concepts
that I would like to underscore
with you from this paper.
The first one is that
the mechanism of fibrosis
and the resultant organ failure
account for at least one-third
of deaths worldwide.
And this has not been
recognized properly before,
and that means
that fibrosis together
with other cause of disease
is a major driver in mortality
in every country in the world.
The second concept is that
fibrosis having adverse effects,
basically in all organs,
is a very attractive
therapeutic target,
and even more so because,
and it is the third concept
I would like to discuss with you,
is that contrary to
the widely held perception
that scar is permanent,
we know now from animal models
and from preclinical data
that there is evidence
pointing to the fact
that organ fibrosis
is highly plastic in nature.
That means that the idea
of potentially revert fibrosis
is something that
needs to be considered
as an achievable target
for any therapeutical trial.